Latest Healthcare Sector News

Epsilon Healthcare Limited is poised to return to ASX trading on 19 December 2025 after satisfying the exchange's conditions for reinstatement.

PeopleIN Limited has announced the sale of its Health and Community brands to Healthcare Australia for $20.25 million, unlocking capital to fuel growth in infrastructure, defence, and agriculture sectors.

Arena REIT has declared a quarterly distribution of 4.8125 cents per security, aligning with its FY26 guidance, while offering a discounted Dividend Reinvestment Plan to investors.

Receivers and administrators have been appointed to 54 pharmacies within the Infinity Retail Pharmacy Group, catching Paragon Care off guard despite ongoing debt restructuring talks. The company pledges to support an orderly resolution to maximise creditor returns.

Anatara Lifesciences reports encouraging pre-clinical results for its anti-obesity candidate AOC, demonstrating significant reductions in weight regain and visceral fat in mice. However, a delay in mechanism of action studies pushes full data release to January 2026.

Paragon Care Limited is set to acquire Indonesian medical aesthetics leader Haju Medical for A$70 million, aiming to boost its footprint across Asia Pacific and accelerate growth in the aesthetics sector.

CD Private Equity Fund II reported a reduced net loss of $2.43 million for the half-year to September 2025, supported by $9.45 million in distributions from portfolio realisations. Despite foreign exchange headwinds, the Fund maintains a diversified portfolio and a positive long-term return track record.

SDI Limited reported stable FY25 revenue with improved margins and advancing Montrose project, while regional sales showed mixed results.

Mayne Pharma’s acquisition by Cosette Pharmaceuticals faces a brief delay as FIRB extends its approval deadline, prompting a reschedule of the critical court hearing to November 23.

Pro Medicus Limited’s U.S. arm has secured a significant five-year, A$44 million contract to deploy its cloud-based Visage 7 imaging platform with Advanced Radiology Management, marking a strategic expansion in North America.

Navigator Global Investments delivered record financial results in FY25, driven by strong revenue growth and strategic expansion, while suspending dividends to fuel future growth. Key leadership changes mark a new chapter for the alternative asset manager.

The Foreign Investment Review Board has extended its deadline for approving Mayne Pharma's acquisition by Cosette Pharmaceuticals, maintaining the current transaction timetable for now.